Antibe Therapeutics Inc.
ATBPF
$0.2156
$0.025613.47%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.24% | 2.49% | 1.89% | -16.35% | -16.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.50% | -17.60% | -19.92% | -23.38% | -14.74% |
| Operating Income | 14.50% | 17.60% | 19.92% | 23.38% | 14.74% |
| Income Before Tax | 17.75% | 22.65% | 24.62% | 27.22% | 19.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.75% | 22.65% | 24.62% | 27.22% | 19.72% |
| Earnings from Discontinued Operations | -265.26% | -160.68% | -225.60% | -184.34% | 254.42% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.63% | 18.46% | 23.10% | 26.02% | 20.75% |
| EBIT | 14.50% | 17.60% | 19.92% | 23.38% | 14.74% |
| EBITDA | 84.70% | 66.21% | 43.64% | 23.07% | 14.10% |
| EPS Basic | 16.43% | 19.25% | 23.83% | 28.29% | 27.14% |
| Normalized Basic EPS | 18.52% | 23.43% | 25.36% | 29.44% | 24.54% |
| EPS Diluted | 16.43% | 19.25% | 23.83% | 28.29% | 27.14% |
| Normalized Diluted EPS | 18.52% | 23.43% | 25.36% | 29.44% | 24.54% |
| Average Basic Shares Outstanding | 0.91% | 0.99% | 0.97% | 2.99% | 8.40% |
| Average Diluted Shares Outstanding | 0.91% | 0.99% | 0.97% | 2.99% | 8.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
